Clinical Trial Detail

NCT ID NCT03101566
Title Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

biliary tract cancer

Therapies

Cisplatin + Gemcitabine + Nivolumab

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.